Giorgio Vittorio Scagliotti, MD, PhD, chief of the Medical Oncology Division at the S. Luigi Hospital, Orbassano (Torino), and head of the Department of Oncology at University of Torino, Italy, discusses the utilization of molecular profiling to inform treatment decisions for patients with non-small cell lung cancer.
Giorgio Vittorio Scagliotti, MD, PhD, chief of the Medical Oncology Division at the S. Luigi Hospital, Orbassano (Torino), and head of the Department of Oncology at University of Torino, Italy, discusses the utilization of molecular profiling to inform treatment decisions for patients with nonsmall cell lung cancer (NSCLC).
The use of next-generation sequencing (NGS), which involes a number of available platforms, is more than a clinical exercise, Scagliotti says. This is especially true in lung cancer, an area where a few oncogenic drivers can be targeted in clinical practice.
Clinicians can also request testing for a limited number of genes, which is what is recommended in the 2018 College of American Pathologists (CAP) guidelines. These recommend testing forEGFRmutations, including T790M,ALKtranslocations,ROS1fusions, andBRAFmutations.RETfusions are still a matter of research and are extremely rare, he adds.
Biomarker Testing Paves the Way for Better Targeted Therapies in NSCLC
April 16th 2024At a live virtual event, Edward S. Kim, MD, MBA, discussed the evolving landscape of biomarker testing before making treatment decisions for patients with early-stage non–small cell lung cancer (NSCLC).
Read More
PTCy Offers New Hope for Mismatched Stem Cell Transplants in Leukemia, MDS
April 13th 2024Jeff Auletta, MD, discussed how PTCy-based graft-vs-host disease prophylaxis offers a promising approach for expanding access to successful cell transplantation regardless of donor match or patient ethnicity.
Read More